Efficacy and Safety of Intravenous Immunoglobulin (IVIg) in Acute Viral Myocarditis in Children: A Systematic Review of Randomized Controlled Trials
No Thumbnail Available
Date
2025-01
Journal Title
Journal ISSN
Volume Title
Publisher
Indian Academy of Pediatrics
Abstract
CONTEXT Acute myocarditis is a rare but potentially life-threatening condi?on in infants and children. While immunosuppressive agents have shown limited effec?veness, intravenous immunoglobulin (IVIg) holds promise as a treatment op?on. OBJECTIVE To study the efficacy and safety of intravenous immunoglobulin (IVIg) in trea?ng acute viral myocardi?s in children. EVIDENCE ACQUISITION We searched five databases including PubMed, EMBASE, the Cochrane Library, Scopus, and Web of Science; and four trial registries for published studies on the topic. Grey literature was searched through ProQuest and Open Grey databases. The studies eligible for this review were randomized controlled trials in children (< 18 years) with acute viral myocardi?s (Popula?on), comparing IVIg (Interven?on), versus no IVIg i.e., any other treatment or placebo (Comparator), for efficacy and safety (Outcomes). RESULTS The literature search iden?fied a total of 9,524 records. Two reviewers independently screened these records. A total of 73 cita?ons were deemed poten?ally eligible, all of which were non-RCTs or review ar?cles on full text examina?on. There were no RCTs iden?fied to address the review ques?on. CONCLUSION There are no RCTs in children comparing the efficacy and safety of IVIg treatment in acute viral myocardi?s. Prospec?ve randomized trials are urgently required.
Description
Keywords
Cardiac, Immunosuppression, Pediatrics, Systematic review
Citation
Jain Lovely, Kaur Davinder, Khalil Sumaira, Pradhan Pranita, Malik Meenakshi, Dogra Sarita, Kaur Kulbir, Mathew Joseph L. Efficacy and Safety of Intravenous Immunoglobulin (IVIg) in Acute Viral Myocarditis in Children: A Systematic Review of Randomized Controlled Trials. Indian Pediatrics. 2025 Jan; 62(1): 56-62